K-NK003

N/A

Report date: 2025/01/07 15:46:23

Base Information

Drug NameK-NK003

Drug Alias NameCD56bright/CD16bright NK-cell adoptive immunotherapyFC21-NK cell therapyCD38KO NK cell therapyK-NK003

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionNatural killer cell replacements

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesBrazil

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesKiadis Pharma

China Registration ClassN/A

Develop Information

Active CompaniesHospital De Clínicas De Porto Alegre Kiadis Pharma

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A